GSK plc

GSK plc Assets per Share

The Total Assets per Share of GSK plc (GSK.L) as of Nov 18, 2026 is 14.85 GBP. In the previous year, Total Assets per Share was 14.44 GBP — a change of 2.78% (higher).

Assets per Share

14.85GBP

YoY

2.78%

Last updated:

Total Assets per Share of GSK plc is 2025 14.85 GBP. Total Assets per Share of GSK plc was 2024 14.44 GBP. It decreases by 2.78% higher compared to the previous year.

The GSK plc Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
14.10 GBP
Jan 1, 2019
19.36 GBP
Jan 1, 2020
19.54 GBP
Jan 1, 2021
19.21 GBP
Jan 1, 2022
14.61 GBP
Jan 1, 2023
14.33 GBP
Jan 1, 2024
14.44 GBP
Jan 1, 2025
14.85 GBP
The GSK plc Assets per Share history
YEARAssets per ShareYoY
14.85GBP+2.78%
14.44GBP+0.78%
14.33GBP-1.90%
14.61GBP-23.96%
19.21GBP-1.65%
19.54GBP+0.93%
19.36GBP+37.24%
14.10GBP+2.99%
13.69GBP-4.57%
14.35GBP+10.54%
12.98GBP+31.48%
9.87GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Total Assets per Share of GSK plc is 14.85 GBP in 2025.

Total Assets per Share of GSK plc changed from 14.44 GBP to 14.85 GBP, representing a 2.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share GSK plc since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — GSK plc

All Key Metrics — GSK plc